Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accelerated Approval Status Disclosure Would Be Mandated By Markey Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Sponsors would be required to inform patients and physicians if a product received accelerated approval under legislation to be introduced by Rep. Ed Markey (D-Mass.). Report by Markey’s office finds that 50% of outstanding postmarketing study requirements have not been started.

You may also be interested in...



FDA Safety Act Proposes Fines For Failure To Comply With Drug Safety Office

Center for Postmarket Drug Evaluation & Research would be able to levy fines starting at $250,000 for failure to complete postmarketing studies on time and for failure to comply with "corrective actions" under the legislation. FDASA would give the independent drug safety office authority over labeling changes and promotional materials.

Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit

Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel